Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company developing therapeutic antibodies and vaccines that selectively target toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases. News about ProMIS frequently centers on its lead Alzheimer’s disease program, PMN310, and the company’s biomarker-driven clinical strategy.
Investors following PMN can expect regular updates on the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer’s disease. Company releases describe PRECISE-AD as a randomized, double-blind, placebo-controlled, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics and biomarker effects of PMN310 in patients with mild cognitive impairment due to AD and mild AD. News items have highlighted enrollment milestones, DSMB recommendations to proceed to higher dose cohorts, and reports that no amyloid-related imaging abnormalities (ARIA) or treatment-related serious adverse events were observed in the cohorts discussed.
ProMIS also issues news on peer-reviewed publications and scientific analyses related to its approach. Recent communications describe publications on the relationship between antibody selectivity for soluble amyloid-beta oligomers and clinical efficacy, as well as analyses supporting plasma phosphorylated tau (pTau) as a potential early predictor of clinical benefit. These publications are referenced by the company as supporting its focus on oligomer-only targeting and its use of plasma pTau as a central endpoint in PRECISE-AD.
Additional PMN news covers corporate and regulatory developments, including the granting of FDA Fast Track designation for PMN310, participation in healthcare investment conferences, board appointments, and capital markets actions such as a one-for-twenty-five reverse stock split and at-the-market offering arrangements. Together, these updates provide context on ProMIS Neurosciences’ clinical progress, scientific rationale and financing activities for those tracking PMN stock and its Alzheimer’s and broader neurodegeneration pipeline.
ProMIS Neurosciences (Nasdaq: PMN) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. The company will host a fireside chat at 9:30 AM ET on February 11 and hold investor one-on-one meetings.
A live webcast of the fireside chat will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
ProMIS Neurosciences (NASDAQ: PMN) entered a PIPE to raise up to $175 million via issuance of common shares, pre-funded warrants and common share warrants. Upfront gross proceeds are expected to be approximately $75 million, with up to an additional $100 million if warrants are fully exercised.
The financing is expected to close on February 3, 2026, extends cash runway into 2028, and is intended to fund completion of the Phase 1b Alzheimer’s study and subcutaneous formulation development. Blinded 6-month topline data are expected mid-2026 and 12-month topline data toward end of 2026.
ProMIS Neurosciences (NASDAQ: PMN) completed enrollment of 144 patients in the PRECISE-AD Phase 1b trial of PMN310 for early Alzheimer’s disease, exceeding its target. The randomized, double-blind, placebo-controlled 12-month study will assess safety, tolerability, pharmacokinetics, biomarkers, and clinical effects of an antibody selective for toxic soluble amyloid-beta oligomers.
To date PMN310 shows a favorable safety profile with limited discontinuations and no treatment-related serious adverse events. A blinded 6-month interim analysis is planned for Q2 2026 and final unblinded top-line results for Q4 2026.
ProMIS Neurosciences (Nasdaq: PMN) reported a peer‑reviewed publication linking clinical efficacy of Aβ antibodies to selective binding of soluble toxic Aβ oligomers. The study found PMN310 preserved oligomer binding despite high monomer concentrations, showed no detectable plaque or vascular binding, and produced no microhemorrhages in high‑dose, chronic plaque‑bearing mice. ProMIS said PRECISE‑AD enrollment is on track to finish by end of 2025, with a 6‑month interim readout planned for Q2 2026 and top‑line results expected in Q4 2026.
ProMIS Neurosciences (Nasdaq: PMN) announced a peer‑reviewed cross‑trial analysis showing plasma pTau181/217 as a potential early predictive endpoint in Alzheimer’s trials. The analysis reported a strong group‑level correlation (≈ 0.78) between 6‑month plasma pTau changes and 12‑month CDR‑SB outcomes, an effect size on plasma pTau ~2.6× larger than clinical change, and simulations indicating well‑powered POC trials could require ~100 participants. ProMIS says these findings align with PRECISE‑AD’s biomarker‑centric design and support a planned blinded 6‑month biomarker readout, including pTau217, expected in Q2 2026.
ProMIS Neurosciences (Nasdaq: PMN) announced that CEO Neil Warma will speak at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance includes a fireside chat at 3:25 PM ET and investor one-on-one meetings.
A live webcast of the presentation will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
ProMIS Neurosciences (Nasdaq: PMN) will effect a one-for-twenty-five reverse stock split of its common shares at 12:01 a.m. ET on November 28, 2025. The split will reduce outstanding shares from approximately 53,811,110 to approximately 2,152,444 and a new CUSIP 74346M505 will be assigned.
Proportional adjustments will be made to equity awards, options, warrants and exercise prices; fractional shares will be settled in cash. The board says the split is intended to increase the market price and cure a Nasdaq bid-price deficiency; Nasdaq extended the company’s compliance period to December 29, 2025.
ProMIS Neurosciences (Nasdaq: PMN) reported Q3 2025 results and corporate updates on Nov 12, 2025. The company said its Phase 1b PRECISE-AD trial of PMN310 is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 expected to complete enrollment before year-end.
PMN310 continues to show a favorable safety profile; the DSMB cleared progression to the third dose cohort. ProMIS expects 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cash was $15.4M at Sept 30, 2025, after July financing that generated ~$21.6M gross proceeds. Q3 R&D expense was $9.8M (Q3 2024: $2.6M); operating loss was $11.8M (Q3 2024: $4.4M).
ProMIS Neurosciences (NASDAQ: PMN) announced management will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025. CEO Neil Warma and senior management will take part in a fireside chat from 11:00–11:25 AM ET and hold investor one-on-one meetings. A live webcast will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
ProMIS Neurosciences (Nasdaq: PMN) appointed Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group’s Public Equity strategy, to its Board of Directors on October 22, 2025. Dr. Alex brings sell-side and buy-side biotech investing experience, pharmacy credentials, and capital-markets expertise. Ally Bridge Group is described as one of ProMIS’ largest shareholders and recently invested in July 2025. The company cited planned PRECISE-AD data readouts for PMN310 in 2Q26 and 4Q26 and said Dr. Alex will support late-stage development planning.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
